Clinical trial NCT02791217: Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool
Official title: Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lymphoma, B-Cell
Follicular Lymphoma
Hodgkin Lymphoma
Multiple Myeloma
Lead sponsor: Assuta Medical Center
Sponsor class: OTHER
Collaborators: name: Laniado Hospital
First posted: 2016-06-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diffused Large B cell Lymphoma Follicular Lymphoma Multiple Myeloma Hodgkin Lymphoma Healthy individuals

Brief summary: MiRNAs are small (\~19-25 nucleotides) non-coding RNA molecules that bind to mRNA in a sequence-specific manner. MiRNAs regulate gene expression at the post-transcriptional level. MiRNAs regulate critical cell processes such as metabolism, apoptosis, development, cell cycle, hematopoietic differentiation and have been implicated in the development and progression of several types of cancers, including hematological malignancies. Over-expression, amplification and/or deletion of miRNAs and miRNA-mediated modification of epigenetic silencing can all lead to oncogenic pathways.

Hematologic cancers, which are caused by the malignant transformation of bone marrow cells and the lymphatic system, are usually divided into three major clusters: leukemia, lymphoma, and multiple myeloma. To date, some of the hematological malignancies are very aggressive that early diagnosis is essential for improving prognosis and increasing survival rates. However, current diagnostic methods have various limitations, such as insufficient sensitivity, specificity, it is also time-consuming, costly, and requires a high level of expertise, which limits its application in clinical contexts. Thus, development of new biomarkers for the early detection and relapse of hematological malignancies is desirable.

Some of the innate properties of miRNAs make them highly attractive as potential biomarkers. MiRNAs can be readily detected in small volume samples using specific and sensitive quantitative real-time PCR; they have been isolated from most body fluids, including serum, plasma, urine, saliva, tears and semen and are known to circulate in a highly stable, cell-free form. They are highly conserved between species, allowing the use of animal models of disease for pre-clinical studies. Furthermore, tumor cells have been shown to release miRNAs into the circulation and profiles of miRNAs are altered in the plasma and/or serum of patients with cancer. A growing number of publications confirm that miRNAs can be a useful biomarker for hematological malignancies diagnosis and progression.


Eligibility criteria: Inclusion Criteria:

* Newly diagnose patients with: Diffused large B cell lymphoma, Follicular lymphoma, Multiple myeloma and Hodgkin lymphoma.
* Patients after chemotherapy (5-30 days).
* Above age 18.

Exclusion Criteria:

* Non-HIV/HCV/HBV Below age 18.

Primary outcomes:
measure: Molecular characteristics (by GEP, miRNA)
timeFrame: 1 year
Secondary outcomes:
measure: Event free survival (EFS)
timeFrame: 0-5 years
measure: Overall survival (OS)
timeFrame: 0-5 years
Other outcomes:
Locations:
Study officials:
References: